Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 6, 2006, Pages 777-785

  Bini, E J ^a,b   Mehandru, S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; REBETRON; VIRUS RNA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS QUALITY OF LIFE QUESTIONNAIRE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SAMPLE SIZE; SHORT FORM 36; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS LOAD;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; QUALITY OF LIFE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 33644751631     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02819.x     Document Type: Article

References (43)

1. National Institutes of Health National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002 Hepatology 2002 36 S3 20
2. Conry-Cantilena C VanRaden M Gibble J et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection N Engl J Med 1996 334 1691 6
3. Inglesby TV Rai R Astemborski J et al. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use Hepatology 1999 29 590 6
4. Nutt AK Hassan HA Lindsey J Lamps LW Raufman JP. Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels Am J Med 2000 109 62 4
5. Puoti C Bellis L Martellino F et al. Chronic hepatitis C and 'normal' ALT levels: treat the disease not the test J Hepatol 2005 43 534 5
6. Alberti A Noventa F Benvegnu L Boccato S Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection Ann Intern Med 2002 137 961 4
7. Gholson CF Morgan K Catinis G et al. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study Am J Gastroenterol 1997 92 1788 92
8. Strader DB Wright T Thomas DL Seeff LB. Diagnosis, management, and treatment of hepatitis C Hepatology 2004 39 1147 71
9. National Institutes of Health National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C Hepatology 1997 26 2S 10S
10. Ishak K Baptista A Bianchi L et al. Histological grading and staging of chronic hepatitis J Hepatol 1995 22 696 9
11. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment J Hepatol 1991 13 372 4
12. Bayliss MS Gandek B Bungay KM Sugano D Hsu MA Ware JE Jr. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C Qual Life Res 1998 7 39 55
13. Ware JE Jr. Hepatitis Quality of Life Questionnaire (HQLQ) Scoring Documentation Lincoln RI QualityMetric Incorporated 1999
14. Ware JE Jr. Kosinski M Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual
15. Tassopoulos NC Vafiadis I Tsantoulas D et al. IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study J Interferon Cytokine Res 2002 22 365 9
16. Mamori S Suzuki F Hosaka T et al. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment J Gastroenterol 2004 39 776 82
17. Shiffman ML Stewart CA Hofmann CM et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy J Infect Dis 2000 182 1595 601
18. Rossini A Ravaggi A Biasi L et al. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis Hepatology 1997 26 1012 7
19. Ohmiya M Hayashi J Ueno K et al. Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels Dig Dis Sci 2000 45 1953 8
20. Srinivas D Mani H Crumpler CC Van Thiel DH. Daily interferon monotherapy for chronic hepatitis C in patients with normal or near-normal serum alanine transaminase levels: a comparison of two protocols South Med J 2005 98 164 9
21. Tran A Longo F Ouzan D et al. Effects of 1-year interferon-alpha 2a treatment in patients with chronic hepatitis C and persistently normal transaminase activity Scand J Gastroenterol 2000 35 433 7
22. Sangiovanni A Morales R Spinzi G et al. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study Hepatology 1998 27 853 6
23. Van Thiel DH Caraceni P Molloy PJ et al. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy J Hepatol 1995 23 503 8
24. Serfaty L Chazouilleres O Pawlotsky JM Andreani T Pellet C Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity Gastroenterology 1996 110 291 5
25. Silverman AL Piquette DL Filipiak CL Neill JS Bayati N Gordon SC. Alfa interferon treatment of hepatitis C virus RNA-positive patients with normal or near-normal alanine aminotransferase levels Am J Gastroenterol 1997 92 1793 5
26. Sakugawa H Nakasone H Nakayoshi T et al. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT Hepatogastroenterology 2003 50 165 9
27. Yagura M Murai S Kojima H Tokita H Kamitsukasa H Harada H. Interferon treatment in patients with chronic hepatitis C with normal alanine aminotransferase activity Hepatogastroenterology 1999 46 1094 9
28. Orito E Mizokami M Suzuki K et al. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment J Gastroenterol Hepatol 1997 12 58 61
29. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels Hepatology 2002 36 S179 84
30. Thevenot T Regimbeau C Ratziu V Leroy V Opolon P Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update J Viral Hepat 2001 8 48 62
31. Carithers RL Jr. Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials Hepatology 1997 26 83S 8S
32. McHutchison JG Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C Semin Liver Dis 1999 19 Suppl. 1 57 65
33. Lee SS Sherman M. Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values J Viral Hepat 2001 8 202 5
34. Hasan F Asker H Al Khalid J et al. Interferon-alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients with persistently normal aminotransferase levels Digestion 2002 65 127 30
35. Erhardt A Behlen-Wilm U Adams O Donner A Heintges T Haussinger D. Combination treatment of IFNalpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs Dig Dis Sci 2003 48 921 5
36. Hui CK Monto A Belaye T Lau E Wright TL. Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases Gut 2003 52 1644 8
37. Mangia A Spinzi G Vuturo O et al. Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study Aliment Pharmacol Ther 2004 19 331 7
38. Jacobson IM Ahmed F Russo MW et al. Interferon alfa-2b and ribavirin for patients with chronic hepatitis C and normal ALT Am J Gastroenterol 2004 99 1700 5
39. McHutchison JG Gordon SC Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 1998 339 1485 92
40. Muir AJ Bornstein JD Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites N Engl J Med 2004 350 2265 71
41. Howell C Jeffers L Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop Gastroenterology 2000 119 1385 96
42. Zeuzem S Diago M Gane E et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels Gastroenterology 2004 127 1724 32
43. Spiegel BM Younossi ZM Hays RD Revicki D Robbins S Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment Hepatology 2005 41 790 800